Dupilumab side effect in a patient with atopic dermatitis: a case report study

Sakhar S Albader,1 Abdulmajeed A Alharbi,2 Rakan F Alenezi,1 Fahad M Alsaif31College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, Alqassim University, Qassim, Saudi Arabia; 3Division of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi ArabiaAbst...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Albader SS, Alharbi AA, Alenezi RF, Alsaif FM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Atopic dermatitis Dupilumab Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c8e5c67d63544b7c94d0155032748adc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c8e5c67d63544b7c94d0155032748adc
record_format	dspace
spelling	oai:doaj.org-article:c8e5c67d63544b7c94d0155032748adc2021-12-02T03:37:38ZDupilumab side effect in a patient with atopic dermatitis: a case report study1177-5491https://doaj.org/article/c8e5c67d63544b7c94d0155032748adc2019-05-01T00:00:00Zhttps://www.dovepress.com/dupilumab-side-effect-in-a-patient-with-atopic-dermatitis-a-case-repor-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Sakhar S Albader,1 Abdulmajeed A Alharbi,2 Rakan F Alenezi,1 Fahad M Alsaif31College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, Alqassim University, Qassim, Saudi Arabia; 3Division of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi ArabiaAbstract: Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration approved dupilumab for treatment of adults with moderate to severe atopic dermatitis not well controlled with topical therapies or when other therapies are inadvisable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. There are many adverse effects reported after dupilumab therapy; commonly reported adverse effects include local injection site reactions, conjunctivitis, headache, and nasopharyngitis. Some adverse effects are rare, eg, alopecia areata and cicatricial extropion. We report a new case of a 28-year-old female who experienced face and neck rash after dupilumab injection.Keywords: atopic dermatitis, dupilumab, eczema, adverse effectAlbader SSAlharbi AAAlenezi RFAlsaif FMDove Medical PressarticleAtopic dermatitisDupilumabMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 13, Pp 79-82 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Atopic dermatitis Dupilumab Medicine (General) R5-920
spellingShingle	Atopic dermatitis Dupilumab Medicine (General) R5-920 Albader SS Alharbi AA Alenezi RF Alsaif FM Dupilumab side effect in a patient with atopic dermatitis: a case report study
description	Sakhar S Albader,1 Abdulmajeed A Alharbi,2 Rakan F Alenezi,1 Fahad M Alsaif31College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, Alqassim University, Qassim, Saudi Arabia; 3Division of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi ArabiaAbstract: Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration approved dupilumab for treatment of adults with moderate to severe atopic dermatitis not well controlled with topical therapies or when other therapies are inadvisable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. There are many adverse effects reported after dupilumab therapy; commonly reported adverse effects include local injection site reactions, conjunctivitis, headache, and nasopharyngitis. Some adverse effects are rare, eg, alopecia areata and cicatricial extropion. We report a new case of a 28-year-old female who experienced face and neck rash after dupilumab injection.Keywords: atopic dermatitis, dupilumab, eczema, adverse effect
format	article
author	Albader SS Alharbi AA Alenezi RF Alsaif FM
author_facet	Albader SS Alharbi AA Alenezi RF Alsaif FM
author_sort	Albader SS
title	Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_short	Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_full	Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_fullStr	Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_full_unstemmed	Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_sort	dupilumab side effect in a patient with atopic dermatitis: a case report study
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/c8e5c67d63544b7c94d0155032748adc
work_keys_str_mv	AT albaderss dupilumabsideeffectinapatientwithatopicdermatitisacasereportstudy AT alharbiaa dupilumabsideeffectinapatientwithatopicdermatitisacasereportstudy AT alenezirf dupilumabsideeffectinapatientwithatopicdermatitisacasereportstudy AT alsaiffm dupilumabsideeffectinapatientwithatopicdermatitisacasereportstudy
_version_	1718401698020458496

Dupilumab side effect in a patient with atopic dermatitis: a case report study

Ejemplares similares